Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia

Inclusion Criteria:

   - Histologically confirmed* diagnosis of 1 of the following:

      - Recurrent or refractory solid tumor or lymphoma (for patients in group 1)

         - Measurable or evaluable disease

      - Recurrent or refractory leukemia (for patients in group 2)

         - Greater than 25% blasts in the bone marrow (i.e., M3 bone marrow)

         - Active extramedullary disease allowed except leptomeningeal disease

      - Recurrent or refractory CNS tumor of 1 of the following types (for patients in
      group 3):

         - Neuroblastoma

         - Medulloblastoma/CNS primitive neuroectodermal tumor

         - Atypical teratoid rhabdoid tumor

   - No known curative therapy or therapy proven to prolong survival with an acceptable
   quality of life exists

   - No bone marrow involvement by disease (for patients in groups 1 and 3)

   - No active CNS leukemia

   - Performance status - Lansky 50-100% (for patients ≤ 10 years of age)

   - Performance status - Karnofsky 60-100% (for patients > 10 years of age)

   - Absolute neutrophil count ≥ 1,000/mm^3 (for solid tumor patients)

   - Platelet count ≥ 100,000/mm^3* (for solid tumor patients) (20,000/mm^3** for leukemia
   patients)

   - Hemoglobin ≥ 8.0 g/dL (RBC transfusion allowed) (for solid tumor and leukemia
   patients)

   - Triglycerides < 300 mg/dL (for patients in group 3)

   - Bilirubin ≤ 1.5 times upper limit of normal (ULN)

   - ALT ≤ 5 times ULN

   - Albumin ≥ 2 g/dL

   - Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min

   - Creatinine based on age as follows:

      - No greater than 0.8 mg/dL (for patients ≤ 5 years of age)

      - No greater than 1.0 mg/dL (for patients 6 to 10 years of age)

      - No greater than 1.2 mg/dL (for patients 11 to 15 years of age)

      - No greater than 1.5 mg/dL (for patients over 15 years of age)

   - Negative dipstick for protein OR < 1,000 mg protein/24 hour urine collection (for
   patients in group 3)

   - No evidence of gross hematuria (for patients in group 3)

   - Not pregnant or nursing

   - Negative pregnancy test

   - Fertile patients must use effective contraception

   - Body surface area ≥ 0.5 m^2

   - Neurologic deficits in patients with CNS tumors must be stable for ≥ 1 week before
   study entry

   - Able to swallow whole capsules

   - No uncontrolled infection

   - Skin toxicity < grade 1 (for patients in group 3)

   - Recovered from prior immunotherapy

   - At least 7 days since prior hematopoietic growth factors

   - At least 7 days since prior antineoplastic biologic agents

   - At least 2 months since prior stem cell transplantation or rescue

      - No evidence of active graft-versus-host disease

   - No other concurrent biologic therapy or immunotherapy

   - More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)
   and recovered

   - No concurrent chemotherapy

   - Patients with CNS tumors must be on a stable or decreasing dose of dexamethasone for ≥
   7 days prior to study entry

   - No concurrent dexamethasone for antinausea or antiemetic therapy

   - Recovered from prior radiotherapy

   - At least 2 weeks since prior local, palliative, small-port radiotherapy

   - At least 3 months since prior total-body irradiation, radiotherapy to the craniospinal
   area, or radiotherapy to ≥ 50% of the pelvis

   - At least 6 weeks since other prior substantial radiotherapy to the bone marrow

   - No concurrent radiotherapy

   - At least 2 weeks since prior valproic acid

   - No other concurrent investigational agents

   - No other concurrent anticancer therapy

   - No concurrent enzyme-inducing anticonvulsants